Approval · Notice of Compliance 31158 · 2023
DELSTRIGO: Notice of Compliance 31158
Issued July 6, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31158
- Date
- July 6, 2023
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of the indication for the treatment of human immunodeficiency virus 1 (HIV-1) infection to pediatric patients 12 years and older and weighing at least 35 kg. Product Monograph (PM) update to the master template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DELSTRIGO | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 300 MG per TAB
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB
- DORAVIRINE 100 MG per TAB